Quality of life (QoL) of cancer patients after treatment may not only be affected by
the treatment itself, but also by non-treatment related factors such as co-morbidity. As co-morbidity among prostate cancer patients is prevalent it is relevant to understand its impact on QoL. In this reagard, a comparison with a normal reference population may help to understand the relevance of the impact of treatment and nontreatment related factors on QoL.